3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Synovitis, Pigmented Villonodular
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Head and Neck Neoplasms
1
Glioma
1
Giant Cell Tumor of Tendon Sheath
1
Carcinoma, Hepatocellular
1
Advanced Pancreatic Cancer
1
Advanced Malignancies
1
Interventions
Paclitaxel
96
Carboplatin
81
Bevacizumab
62
Gemcitabine
36
liposomal doxorubicin
32
pembrolizumab
30
Topotecan
26
olaparib
23
Taxes
23
niraparib
17
Immunoglobulin G
17
Disulfides
17
Docetaxel
16
Cyclophosphamide
16
Cisplatin
14
Nivolumab
11
rucaparib
10
durvalumab
10
Doxorubicin
9
Albumin-Bound Paclitaxel
8
sargramostim
7
pazopanib
7
fludarabine phosphate
7
fludarabine
7
avelumab
7
Magnetic Resonance Spectroscopy
7
Ifosfamide
7
epacadostat
6
Trabectedin
6
Sorafenib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ovarian Neoplasms
×
cabiralizumab
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts